Hepatitis A Vaccines

Global Hepatitis A Vaccines Market to Reach US$891.4 Million by 2030

The global market for Hepatitis A Vaccines estimated at US$784.7 Million in the year 2024, is expected to reach US$891.4 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Inactivated Vaccine, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$572.5 Million by the end of the analysis period. Growth in the Live Attenuated Vaccine segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$213.8 Million While China is Forecast to Grow at 4.1% CAGR

The Hepatitis A Vaccines market in the U.S. is estimated at US$213.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$167.9 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Hepatitis A Vaccines Market – Key Trends & Drivers Summarized

Why Does Hepatitis A Vaccination Remain a Global Public Health Priority?
Hepatitis A, an acute liver infection caused by the Hepatitis A virus (HAV), continues to pose a significant threat in regions with poor sanitation and inadequate access to clean water. The virus spreads primarily through the fecal-oral route and is highly contagious, leading to outbreaks particularly in developing countries and among vulnerable populations such as children, travelers, and people in crowded settings. Although self-limiting in most cases, Hepatitis A can lead to fulminant hepatic failure, particularly in older adults and immunocompromised individuals.

Vaccination remains the most effective method of preventing Hepatitis A infection. Global immunization programs targeting children, travelers, military personnel, food handlers, and healthcare workers have significantly reduced incidence rates in high-risk areas. The increasing frequency of localized outbreaks in both developing and developed nations—often driven by poor hygiene, climate-related water contamination, or international travel—continues to underline the importance of sustained vaccination efforts. Universal childhood immunization and outbreak response strategies are key pillars of long-term disease control.

How Are Vaccine Formulations and Delivery Platforms Evolving?
Hepatitis A vaccines are traditionally inactivated (killed virus) formulations administered in two doses for long-term immunity. Newer advancements are exploring combination vaccines that integrate Hepatitis A with other antigens such as Hepatitis B or typhoid, reducing the number of injections and improving compliance. Pediatric-specific formulations and single-dose regimens for emergency use during outbreaks are being developed to enhance coverage and accessibility.

Improved cold-chain stability, needle-free delivery systems, and adjuvant technologies are expanding vaccine usability in remote or resource-limited settings. Efforts are underway to develop thermostable formulations that maintain potency without refrigeration—an essential feature for expanding outreach in tropical regions. The adoption of digital health tools for tracking immunization records and predicting outbreak hotspots is also enhancing public health deployment and coverage optimization strategies.

Which Regions and Population Segments Are Driving Vaccination Demand?
Endemic regions in Asia-Pacific, Latin America, Africa, and the Middle East represent the largest markets for Hepatitis A vaccines, particularly in rural and underserved areas. Mass immunization campaigns, often supported by global health agencies, are underway in countries like India, China, Indonesia, and Brazil. In developed nations, vaccination is primarily targeted at high-risk groups including international travelers, men who have sex with men (MSM), people experiencing homelessness, and food industry workers.

Tourism and labor migration are also key factors boosting vaccine uptake in non-endemic regions, where Hepatitis A is now considered a travel-associated disease. The education sector and military organizations in many countries are institutionalizing Hepatitis A immunization to protect communal living environments. Routine pediatric immunization programs in countries such as the U.S., Israel, and Australia have successfully reduced incidence rates and are influencing global policy harmonization.

The Growth in the Hepatitis A Vaccines Market Is Driven by Several Factors
The growth in the Hepatitis A vaccines market is driven by increasing incidence of outbreaks, expansion of routine immunization programs, and the global rise in travel-related health risks. The resurgence of Hepatitis A in developed countries due to population movement, urban crowding, and poor hygiene in underserved communities is prompting renewed emphasis on adult and catch-up vaccination programs. Government-backed health campaigns, international aid funding, and school-entry vaccine mandates are amplifying coverage in both endemic and non-endemic regions.

Technological improvements in vaccine formulation, multi-antigen combinations, and thermostable storage solutions are enhancing market accessibility, especially in low-resource settings. Additionally, greater awareness of foodborne and waterborne diseases, employer-mandated vaccinations for specific workforces, and better outbreak surveillance are supporting vaccine demand. As global health systems emphasize preventive care and cross-border disease control, the Hepatitis A vaccine market is positioned for sustained, geographically diverse growth

SCOPE OF STUDY:

The report analyzes the Hepatitis A Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Inactivated Vaccine, Live Attenuated Vaccine); Application (Government Institution, Private Sector, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Bharat Biotech
• Biological E. Limited
• Chiron Behring Vaccines
• Crucell (a Janssen Pharmaceutical Company)
• GlaxoSmithKline plc
• Indian Immunologicals Limited
• LG Chem
• Merck & Co., Inc.
• Panacea Biotec
• Pukang Biotech
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanta Biotechnics
• Sinovac Biotech Ltd.
• SK Bioscience
• Takeda Pharmaceutical Company Limited
• VBI Vaccines Inc.
• Walvax Biotechnology Co., Ltd.
• Zydus Lifesciences Limited
• Zydus Vaccines

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.